Orange Book product · Brand (NDA)
TARGRETIN
BEXAROTENE
At a glance
Jun 28, 2000
Approved
Brand (NDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jun 28, 2000
26 yr 4 mo ago
Today
Pharmaceutical detail
Active ingredient
BEXAROTENE
Strength
1%
Dosage form
GEL
Route
TOPICAL
TE code
AB
Application
NDA 021056
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 1999TARGRETINBrand (NDA)
NDA 021055 · BAUSCH
- 2024BEXAROTENEGeneric (ANDA)
ANDA 210352 · CIPLA
- 2024BEXAROTENEGeneric (ANDA)
ANDA 208628 · ASCENT PHARMS INC
- 2022BEXAROTENEGeneric (ANDA)
ANDA 215398 · AMNEAL
- 2021BEXAROTENEGeneric (ANDA)
ANDA 209931 · TEVA PHARMS USA
- 2020BEXAROTENEGeneric (ANDA)
ANDA 203663 · HIKMA
- 2018BEXAROTENEGeneric (ANDA)
ANDA 210105 · AMNEAL PHARMS NY
- 2018BEXAROTENEGeneric (ANDA)
ANDA 209886 · UPSHER SMITH LABS
- 2018BEXAROTENEGeneric (ANDA)
ANDA 209861 · ANI PHARMS
- 2014BEXAROTENEGeneric (ANDA)
ANDA 203174 · BIONPHARMA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
